Please assess the completion status of the following clinical trial:

Trial Title: Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has provided written informed consent~2. Has adenocarcinoma of the colon or rectum~3. Has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer~4. ECOG performance status of 0 or 1~5. Is able to take medications orally~6. Has adequate organ function (bone marrow, kidney and liver)~7. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.~Exclusion Criteria:~1. Certain serious illnesses or medical condition(s)~2. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration~3. Has received TAS-102~4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies~5. Is a pregnant or lactating female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-102 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).